17 studies found for:    mt103
Show Display Options
Rank Status Study
1 Completed
Has Results
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: Blinatumomab (MT103)
2 Completed
Has Results
Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
Condition: Non-Hodgkin's Lymphoma, Relapsed
Intervention: Biological: Blinatumomab (MT103)
3 Active, not recruiting
Has Results
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Condition: B-ALL
Intervention: Biological: Blinatumomab
4 Active, not recruiting
Has Results
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: B-cell Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
5 Active, not recruiting
Has Results
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: Blinatumomab
6 Recruiting Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: Blinatumomab;   Drug: Prednisone;   Drug: Vincristine Sulfate;   Drug: Methotrexate;   Drug: Mercaptopurine;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis
7 Suspended Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
8 Active, not recruiting Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: blinatumomab
9 Withdrawn A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: MEDI-538
10 Active, not recruiting Phase 2 Trial of Blinatumomab in Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia
Condition: Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
11 Recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
12 Active, not recruiting Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Condition: Diffuse Large B-cell Lymphoma
Intervention: Drug: Blinatumomab
13 Not yet recruiting Study of Blinatumomab in Japanese Adults With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Blinatumomab
14 Recruiting Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Blinatumomab;   Drug: Etoposide;   Drug: Prednisone;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
15 Not yet recruiting Phase 3 Trial of Blinatumomab Versus Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL
Condition: Leukemia, Acute Lymphoblastic
Interventions: Drug: Blinatumomab;   Other: Conventional Consolidation Chemotherapy
16 Withdrawn A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
Conditions: Lymphoma, B-Cell;   Lymphoma, Non-Hodgkin
Intervention: Drug: MEDI-538
17 Available Expanded Access Protocol of Blinatumomab in Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Blinatumomab

Indicates status has not been verified in more than two years